Filing Details

Accession Number:
0001209191-18-001204
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-01-03 17:52:00
Reporting Period:
2018-01-03
Accepted Time:
2018-01-03 17:52:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1590560 Uniqure N.v. QURE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1693817 Jonathan Garen C/O Uniqure N.v.
Paasheuvelweg 25A
Amsterdam P7 P7 1105BP
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2018-01-03 5,864 $20.13 85,251 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. As required by the relevant Restricted Share Unit Agreement, the reporting person sold the ordinary shares and remitted the proceeds therefrom to the issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.66 to $20.47, inclusive. The reporting person undertakes to provide uniQure N.V., any security holder of uniQure N.V. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price ranges set forth in this footnote.
  3. Consists of (i) 11,636 ordinary shares, (ii) 56,115 performance share units that vest in full on January 27, 2020 and (iii) 17,500 restricted stockunits previously disclosed by the reporting person on Table II, that vest in full on December 31, 2018.